From Outbreak to Orphan:
Reflecting on Our FDA Designation
Rare Disease Day is an occasion to take stock of what progress looks like for the patients who can't afford to wait. This year we're marking it by reflecting on a milestone from last October — FDA Orphan Drug Designation for our Zika virus program in glioblastoma — what it means, why it matters, and where it takes us next.
February 28th is Rare Disease Day — an annual reminder that more than 30 million Americans live with conditions that the medical system has historically passed by. For most of the 20th century, the economics of drug development simply didn't work for rare diseases: patient populations too small, development costs too high, return on investment too uncertain. Patients with rare cancers like glioblastoma felt that neglect acutely.
This year, Rare Disease Day gives us the opportunity to reflect on a milestone that UP Oncolytics reached last October: FDA Orphan Drug Designation for one of our proprietary Zika virus (ZIKV) strains targeting glioblastoma multiforme (GBM). The designation signals that the FDA has reviewed the scientific rationale for our approach and recognized a genuine unmet medical need — and it unlocks a suite of concrete advantages that meaningfully improve our development trajectory.
UP Oncolytics was founded on a question asked during the Zika epidemic in the Americas — a conversation between a wife and husband that connected two biological dots no one had yet connected. The full story of how that question became a company, and a scientific program, is worth telling in its own right. We'll be sharing it in a dedicated post during Brain Tumor Awareness Month this May. For now, the short version: it started over dinner, and it may change the way brain cancer is treated.
Why Glioblastoma Is a Rare Disease
Many people are surprised to learn that glioblastoma qualifies as a rare disease under federal law. The Orphan Drug Act defines a rare disease as one affecting fewer than 200,000 Americans. GBM is diagnosed in approximately 15,000 Americans each year — a number that belies the intensity of suffering it causes, but one that places it squarely within the rare disease framework.
What that number cannot convey is the prognosis. GBM is nearly universally fatal. Median overall survival with the current standard of care — surgery, radiation, and temozolomide chemotherapy — remains approximately 15 months, a figure that has not meaningfully changed since the Stupp protocol was established in 2005. At the heart of GBM's lethal resilience is a subpopulation of cells known as glioblastoma stem cells (GSCs): self-renewing, therapy-resistant cells that drive tumor regrowth after treatment and evade immune surveillance with remarkable efficiency.
Any therapeutic approach that cannot address the GSC population is likely to produce only temporary remission before recurrence. This is precisely where our Zika virus platform enters the picture.
Why Zika? The Science Behind the Strategy
During the 2015–2016 Zika epidemic, researchers established that ZIKV causes its devastating fetal effects by targeting neural progenitor cells — the same class of stem-like cells from which GSCs arise and which they biologically resemble. The virus enters these cells primarily through the AXL receptor tyrosine kinase, which is highly expressed on neural progenitor cells and, critically, is frequently overexpressed in GBM.
Our own research was among the first to establish the AXL mechanism in GBM cell lines specifically — demonstrating that AXL expression is required for ZIKV entry, that the level of AXL expression directly predicts infection magnitude, and that ZIKV infection of AXL-expressing GBM cells results in productive, cytotoxic replication. The very receptor that contributes to GBM's aggressive biology appears to be the doorway through which a therapeutic virus can enter.
Rather than engineering our way to safety, we went looking for it in nature. Through our collaboration with the NIH, we identified wild-type ZIKV strains that are naturally, intrinsically minimally neurovirulent in adults — strains whose safety profile is a property of the virus itself, not the result of genetic modification. That safety foundation has since been validated in a completed clinical trial, providing human tolerability data that strengthens the case for advancing into GBM studies.
A further practical advantage: most adult GBM patients in the United States have never been exposed to Zika virus. Pre-existing immunity — which has hampered clinical development of oncolytic candidates based on common viruses like herpes simplex and adenovirus — is unlikely to neutralize our therapeutic before it can engage the tumor.
What Orphan Drug Designation Means — and Why It Matters
When Congress passed the Orphan Drug Act in 1983, fewer than ten drugs for rare diseases were available to patients. The legislation created a suite of incentives designed to correct the market failure that had left rare disease patients without options. Today, orphan-designated approvals represent close to half of all new FDA drug approvals — a remarkable transformation attributable in significant part to the Act's incentive structure.
Receiving ODD is not the same as receiving FDA approval — our ZIKV therapy has not yet been approved, and substantial clinical work lies ahead. But it is a meaningful regulatory milestone, and it unlocks four categories of concrete benefit.
The Core Benefits of Our Designation
The FDA's ODD program provides four categories of concrete benefit to qualifying sponsors:
Upon approval, our designation provides seven years of marketing exclusivity — the FDA cannot approve a competing product with the same active moiety for the same indication during that period.
Qualified clinical trial expenses incurred in the United States are eligible for a 25% federal tax credit, which can be applied to prior-year taxes or carried forward up to 20 years.
The FDA application fee for a new drug or biologics license application — which exceeds $4 million — is waived for orphan-designated products. A material cost saving for a small company.
ODD holders receive formal protocol assistance from the FDA — a structured dialogue about clinical trial design and development strategy that is not available to non-designated programs.
Beyond the statutory benefits, designation signals to prospective partners, investors, and academic collaborators that the FDA has reviewed our scientific rationale and found it credible. For a small company pursuing a first-in-class biologic in a difficult indication, that signal matters.
How We Got Here
The Orphan Drug Act was signed into law by President Ronald Reagan on January 4, 1983, after sustained advocacy from rare disease patient communities who recognized that market forces alone would never address their needs.
What This Means for Our Program
For UP Oncolytics, Orphan Drug Designation is a waypoint, not a destination. The real goal remains ahead: a safe, effective, approved therapy that extends meaningful survival for GBM patients. But ODD changes our development trajectory in concrete ways — the fee waiver preserves capital for research, the tax credit improves the economics of clinical investment, formal FDA protocol assistance reduces development risk, and seven years of post-approval exclusivity creates a commercial foundation that makes continued investment rational.